美股市场个股详情

NRBO NeuroBo Pharmaceuticals

添加自选

3.7648
-0.0152-0.40%

交易中 05/06 09:51 (美东)

1847.01万总市值-1530市盈率TTM

NeuroBo Pharmaceuticals股票讨论区

登录发表评论

Jaguar8

04/30 20:05

$NeuroBo Pharmaceuticals(NRBO.US)$
NEWS
NeuroBo to Present Latest Pre-Clinical Data on Cardiometabolic Assets, DA-1241 and DA-1726, Targeting MASH and Obesity, at Scientific Conferences in June

Equity Wizard

03/01 11:40

醒醒吧

$NeuroBo Pharmaceuticals(NRBO.US)$ $Viking Therapeutics(VKTX.US)$ 一般来说，从药物的发现和前期研究开始，到进行临床试验（第1期、第2期、第3期），再到申请监管审批，整个过程可能需要数年到十几年的时间。每个阶段所需的具体时间长度可以因药物的特性、治疗领域、临床试验设计、以及是否遇到额外的研究或监管挑战等因素而有所不同。 $礼来(LLY.US)$
Eli Lilly的减肥药已经上市。美国食品和药物管理局（FDA）批准了Eli Lilly的Zepbound™ 贵有贵的道理

Stock Region

03/01 08:58

Leading Medical Company Receives FDA Clearance For Obesity Drug Candidate

Groundbreaking Progress in Obesity Treatment: NeuroBo Pharmaceuticals Receives FDA Clearance for Clinical Trial of DA-1726.
In a significant milestone for obesity treatment, NeuroBo Pharmaceuticals, a leading pharmaceutical company, has received FDA clearance to commence a Phase 1 clinical trial for its new drug candidate, DA-1726. This marks a critical advancement in the medical field, with potential far-reaching implicati...